Spyre Therapeutics, Inc. (SYRE) Financial Analysis & Valuation | Quarter Chart
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for t... more
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeut... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $8.34B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Cameron Turtle |
| IPO Date | 2016-04-07 | CAGR | — |
| Employees | 125 | Website | www.spyre.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SYRE chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $6.64B | P/E | -46.32 | Forward P/E | -25.77 | PEG | — |
| P/S | 0.09 | P/B | 0.02 | P/CF | -0.03 | P/FCF | -0.03 |
| Sales | $90.49M | Sales 1Y | inf% | Sales 3Y | 7269.22% | Sales 5Y | 560.73% |
| EPS | $-1.95 | EPS 1Y | -12.95% | EPS 3Y | -97.35% | EPS 5Y | -92.67% |
| Sales QoQ | — | EPS QoQ | -51.35% | Sales QoQ Avg | — | EPS QoQ Avg | 61.51% |
| Gross Margin | — | Operating Margin | -222.49% | Profit Margin | -197.71% | ROCE | -18.14% |
| ROA | -15% | ROE | -24% | Altman Z Score | 69.25 | Piotroski Score | 2 |
| Current Ratio | 18.53 | Quick Ratio | 18.53 | Cash Ratio | 2.56 | Op. CF Ratio | -1.1 |
| Debt/Equity | — | Debt/Assets | — | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.08 | Receivables Turnover | — |
| Enterprise Value | $6.64B | P/E Ratio | -46.32 |
| Forward P/E | -25.77 | PEG Ratio | — |
| P/S Ratio | 0.09 | P/B Ratio | 0.02 |
| P/CF Ratio | -0.03 | P/FCF Ratio | -0.03 |
| EPS | $-1.95 | EPS Growth 1Y | -12.95% |
| EPS Growth 3Y | -97.35% | EPS Growth 5Y | -92.67% |
| Revenue Growth 1Y | inf% | Gross Margin | — |
| Operating Margin | -222.49% | Profit Margin | -197.71% |
| ROE | -24% | ROA | -15% |
| ROCE | -18.14% | Current Ratio | 18.53 |
| Quick Ratio | 18.53 | Cash Ratio | 2.56 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | 69.25 | Piotroski Score | 2 |
Spyre Therapeutics, Inc. (SYRE) valuation & financials
Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $8.34B and trades at a price-to-earnings ratio of -46.3. It operates in the Healthcare sector (Biotechnology).
Spyre Therapeutics, Inc.'s revenue grew — over the last year.
Spyre Therapeutics, Inc.'s next earnings report is scheduled for November 3, 2026 (provider scheduled date); analysts estimate EPS of $-0.78. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)